97,662 Shares in 10x Genomics $TXG Acquired by Fulcrum Asset Management LLP

Posted by George Bondi on Nov 9th, 2026

Fulcrum Asset Management LLP acquired a new position in shares of 10x Genomics (NASDAQ:TXG – Free Report) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 97,662 shares of the company’s stock, valued at approximately $8,793,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Quantinno Capital Management LP increased its position in shares of 10x Genomics by 16.0% during the first quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after purchasing an additional 744,558 shares during the period. Dimensional Fund Advisors LP lifted its position in 10x Genomics by 34.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after purchasing an additional 525,369 shares during the period. Counterpoint Mutual Funds LLC bought a new position in 10x Genomics in the third quarter worth $11,364,000. Quantedge Capital Pte Ltd lifted its position in 10x Genomics by 104.2% in the first quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock worth $8,843,000 after purchasing an additional 212,600 shares during the period. Finally, Hsbc Holdings PLC acquired a new stake in 10x Genomics during the first quarter worth $5,945,000. 84.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TXG. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a report on Monday, September 21st. Argus initiated coverage on shares of 10x Genomics in a research note on Monday, September 28th. They issued a “buy” rating and a $110.00 price objective for the company. Stifel Nicolaus raised their price objective on shares of 10x Genomics from $50.00 to $68.00 and gave the stock a “buy” rating in a report on Friday. Royal Bank Of Canada initiated coverage on shares of 10x Genomics in a research report on Tuesday, September 1st. They set a “sector perform” rating and a $70.00 target price on the stock. Finally, Stephens lowered shares of 10x Genomics from an “overweight” rating to an “equal weight” rating in a research report on Friday, October 23rd. Five analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $68.07.

Check Out Our Latest Stock Analysis on TXG

10x Genomics Stock Performance

Shares of TXG opened at $59.28 on Monday. 10x Genomics has a 1 year low of $13.58 and a 1 year high of $102.81. The stock has a 50 day simple moving average of $73.95 and a 200-day simple moving average of $41.59. The stock has a market cap of $7.72 billion, a PE ratio of -114.00 and a beta of 2.03.

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.12. The business had revenue of $150.67 million during the quarter, compared to the consensus estimate of $147.96 million. 10x Genomics had a negative return on equity of 8.26% and a negative net margin of 10.84%. 10x Genomics’s revenue was up 1.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.22) EPS. On average, sell-side analysts forecast that 10x Genomics will post -0.77 EPS for the current fiscal year.

Key 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

Insider Transactions at 10x Genomics

In other 10x Genomics news, Director John Stuelpnagel sold 20,000 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the completion of the transaction, the director directly owned 328,436 shares in the company, valued at $20,280,923. This represents a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Taich sold 46,388 shares of the stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the transaction, the chief financial officer owned 316,344 shares of the company’s stock, valued at $20,426,332.08. This represents a 12.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is owned by insiders.

10x Genomics Company Profile

(Free Report)

10x Genomics, Inc develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue.

The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves research and clinical customers around the world, including academic institutions, biotechnology and pharmaceutical companies, and other research organizations.